Business
The Opthea (ASX:OPT) share price up after receiving FDA approval
The Opthea Ltd (ASX: OPT) share price is up 8.39% to $1.55 this morning. The rise comes after receiving an initial Pediatric Study Plan (iPSP) waiver from the US Food and Drug Administration (FDA) for OPT-302.
Opthea is committed to improving vision in patients suffering from retinal eye diseases. OPT-302 is the company’s lead product candidate. The product also has the potential to address the unmet medical need within the eye disease market.
Another milestone for the Opthea share price
An iPSP is a pre-requisite for a marketing application of new medicine for a biopharmaceutical company in the US. Additionally, the iPSP provides the…
-
Noosa News9 hours agoWoman dead and man rushed to hospital with gunshot wound following crash near Aussie World on Queensland’s Sunshine Coast
-
General15 hours agoBoy dies after being trapped between rocks off NSW beach
-
Noosa News16 hours agoFarmer Fred Perry’s 30-year conservation project creates bird haven after years of ‘bashing and burning’
-
Noosa News16 hours agoDetectives continue to search for answers on Crystal Beale’s death